Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence

Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully h...

Full description

Saved in:
Bibliographic Details
Published in:Dermatology and therapy 2024-10, Vol.14 (10), p.2739-2757
Main Authors: Malagoli, Piergiorgio, Dapavo, Paolo, Amerio, Paolo, Atzori, Laura, Balato, Anna, Bardazzi, Federico, Bianchi, Luca, Cattaneo, Angelo, Chiricozzi, Andrea, Congedo, Maurizio, Fargnoli, Maria Concetta, Giofrè, Claudia, Gisondi, Paolo, Guarneri, Claudio, Lembo, Serena, Loconsole, Francesco, Mazzocchetti, Giampiero, Mercuri, Santo Raffaele, Morrone, Pietro, Offidani, Anna Maria, Palazzo, Giovanni, Parodi, Aurora, Pellacani, Giovanni, Piaserico, Stefano, Potenza, Concetta, Prignano, Francesca, Romanelli, Marco, Savoia, Paola, Stingeni, Luca, Travaglini, Massimo, Trovato, Emanuele, Venturini, Marina, Zichichi, Leonardo, Costanzo, Antonio
Format: Article
Language:English
Subjects:
Dermatology
Drug therapy
Early treatment
Internal Medicine
Medicine
Medicine & Public Health
Oral and Maxillofacial Surgery
Plastic Surgery
Psoriasis
Quality of Life Research
Review
Secukinumab
Treatment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis. Secukinumab demonstrated long-lasting efficacy and a good safety profile in individuals with plaque psoriasis, and it is associated with an improvement in health-related quality of life. While there is evidence that early treatment with systemic therapy can affect disease progression and improve long-term outcomes in other autoimmune diseases, evidence is limited in psoriasis, especially in real-world settings. This review provides an overview of studies describing the effectiveness of secukinumab in the treatment of psoriasis summarizing the literature and focusing on real-world evidence and early intervention.
ISSN:2193-8210
2190-9172
DOI:10.1007/s13555-024-01255-4